Adma Biologics Stock News

ADMA Biologics Inc. (NASDAQ:ADMA) price is hovering higher on Wednesday, March 02, jumping 0.91% above its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << A look at today’s price movement shows that the recent level at last check reads $1.64, with intraday deals fluctuating between … Investors Cash In On ADMA Biologics Inc.’s 0.91% Gain Read More »

Adma Biologics (ADMA) activist holder Caligan Partners is said to be supportive of the company''s ongoing strategic review

Cheap penny stocks to watch right now. The post 4 Penny Stocks To Buy For Under $4 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH) announced an upward revision

Cheap penny stocks to watch right now. The post 4 Penny Stocks To Buy For Under $4 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest Quarterly Revenue for the Company Since Inception

ADMA Biologics Inc (NASDAQ: ADMA) expects Q4 Sales of approximately $26 million, compared to $14 million a year ago and better than the consensus of $21.76 million.  The preliminary results represe

FDA approval positions Company to meet or exceed target of ten or more FDA-licensed plasma collection centers by year-end 2023 FDA approval positions Company to meet or exceed target of ten or more FD

ADMA Biologics: 2021 Was Tough

ADMA Biologics (NASDAQ: ADMA) recently received a number of ratings updates from brokerages and research firms: 12/22/2021 ADMA Biologics was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They now have a $1.50 price target on the stock. According to Zacks, ADMA Biologics, Inc. is a specialty []

Zacks Investment Research upgraded shares of ADMA Biologics (NASDAQ:ADMA) from a hold rating to a buy rating in a report published on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $1.50 price objective on the biotechnology companys stock. According to Zacks, ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and []

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and

Zacks Investment Research lowered shares of ADMA Biologics (NASDAQ:ADMA) from a buy rating to a hold rating in a research note released on Wednesday, Zacks.com reports. According to Zacks, ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious []

Zacks Investment Research lowered shares of ADMA Biologics (NASDAQ:ADMA) from a buy rating to a hold rating in a report released on Wednesday, Zacks.com reports. According to Zacks, ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. []